1. Introduction {#sec1-nutrients-11-01114}
===============

Cardiovascular disease (CVD) is one of the main causes of death worldwide. The relationship between diets and CVD is complex, although it has been shown that some dietary patterns, such as the Mediterranean diet \[[@B1-nutrients-11-01114]\] or the Nordic diet \[[@B2-nutrients-11-01114]\], elicit cardioprotective effects.

The Nordic diet is characterized by a high intake of foods produced locally, such as salmon and herring (fatty fish); cod; tubercles; pulses; wholegrain cereals such as barley, oats, and rye; berries (which are very rich in polyphenols); and other fruits. Therefore, this diet is especially rich in long-chain omega 3 fatty acids, accompanied by a moderate-to-high intake of fiber, minerals, and antioxidants, and has been shown to improve endothelial function and alleviate proinflammatory states \[[@B2-nutrients-11-01114]\]. Over recent years, this dietary pattern has been the object of increasing interest because it has been associated with decreased overall and cancer mortality, although controversial results have been observed in terms of CVD mortality \[[@B3-nutrients-11-01114]\].

Circulating microvesicles (cMV) are a subtype of extracellular vesicles rich in phospholipids that range from 0.1 to 1 micrometer (µm) diameter and shed from cells when activated, injured, or undergoing apoptotic or necrotic processes. Circulating microvesicles act as procoagulant agents because an externalization of the procoagulant anionic phosphatidylserine (PS) takes place during MV formation. In addition, cMV carry antigens from their cell of origin and have also been found to be involved in inflammatory processes, thus contributing to both the initiation and progression of CVD. In fact, elevated platelet-, endothelial-, and leukocyte-derived cMV have been observed in several CVD states and have been associated with several CVD risk factors, as reviewed in Reference \[[@B4-nutrients-11-01114]\]. The effects of diet on MV shedding have been scarcely investigated (reviewed in Reference \[[@B5-nutrients-11-01114]\]), and the relationship between the Nordic diet and MV generation is largely unknown. Therefore, the aim of our study was to investigate whether the quality of the Nordic diet is associated with MV shedding in elderly patients after an acute myocardial infarction (AMI), which is known to increase the levels of cMV \[[@B6-nutrients-11-01114],[@B7-nutrients-11-01114]\].

2. Materials and Methods {#sec2-nutrients-11-01114}
========================

2.1. Study Population {#sec2dot1-nutrients-11-01114}
---------------------

The subjects included in this cross-sectional study belong to a subset of the "OMega-3 fatty acids in Elderly patients with Myocardial Infarction" (OMEMI; NCT01841944, [Clinical-Trials.gov](Clinical-Trials.gov)) cohort \[[@B8-nutrients-11-01114]\] at inclusion in the study. The protocol was approved by the Regional Committee for Medical Research Ethics (ref. number: 2012/1422). Patients 70--82 years old were recruited at Oslo University Hospital Ullevål, Oslo, Norway, after a diagnosis of an AMI, and were included in the study after 2 to 8 weeks of surviving the AMI. Patients were treated per guidelines with standard medication. Demographic data, clinical characteristics, cardiovascular history, classic cardiovascular risk factors, and current pharmacological treatment were obtained from all subjects using a standardized report form at inclusion. A patient's usual diet was recorded at study entry with the SmartDiet® questionnaire (version 3, from May 2009), which is a fast, simple, and validated tool for the assessment of food intake and diet quality, and results in a diet score \[[@B9-nutrients-11-01114]\]. As shown in [Table 1](#nutrients-11-01114-t001){ref-type="table"}, the SmartDiet score is built upon 14 questions relating to food quantity and quality, which are scored, summed, and categorized as unhealthy (≤ 27 points, group I), somewhat unhealthy (28--35 points, group II), or healthy diet (≥ 36 points, group III), according to the Nordic Nutrition Recommendations. The study protocol was approved by the Regional Committee for Medical Research Ethics and followed the principles outlined in the Declaration of Helsinki. All participants signed their informed consent.

2.2. Blood Sampling {#sec2dot2-nutrients-11-01114}
-------------------

Fasting venous blood was withdrawn into 3.8% sodium citrate tubes for MV analysis. Blood cells were removed by centrifuging whole blood 20 min at 2500× *g* at 4 ºC. Plasma was carefully recollected, leaving about 0.2 cm of an undisturbed layer on top of the cells, and aliquots were immediately frozen and stored at −80 ºC until processing for isolation and quantification of cMV. Additionally, biochemical and hematological parameters were quantified with standardized routine methods.

2.3. Circulating Microvesicle Isolation and Quantification {#sec2dot3-nutrients-11-01114}
----------------------------------------------------------

The cMV fraction was isolated from citrated and anticoagulated plasma through a two-step high-speed centrifugation procedure. Five-hundred microliters (µL) of frozen plasma aliquots were thawed on melting ice and centrifuged again at 2500× *g* for 15 min at room temperature (RT) \[[@B10-nutrients-11-01114]\]. Then, 250 µL of plasma were collected and centrifuged at 20000× *g* for 30 min at RT to pellet cMV. The supernatants were discarded, and the cMV-enriched pellet was washed once with citrate-phosphate buffered saline (PBS) solution (citrate-PBS; 1.4 mM phosphate, 154 mM NaCl, 10.9 mM trisodium citrate, pH 7.4) before a second equal centrifugation step was made. Finally, the remaining cMV pellets were resuspended in 100 µL of citrate-PBS.

A triple-label flow cytometry analysis was performed as described before \[[@B7-nutrients-11-01114],[@B11-nutrients-11-01114]\]. Briefly, 5 µL of washed cMV suspensions were diluted in 30 µL of PBS buffer containing 2.5 mM of CaCl~2~ (Annexin Binding Buffer, ABB). Thereafter, combinations of 5 µL of allophycocyanin (APC)-conjugated Annexin V (AV, BD-horizon) with two specific monoclonal antibodies (mAb, 5 µL each, [Table 2](#nutrients-11-01114-t002){ref-type="table"}) labeled with fluorescein isothiocyanate (FITC) and phycoerythrin (PE) (or the isotype-matched control antibodies) were added.

Samples were incubated for 20 min at RT in the dark and diluted with ABB before being immediately analyzed with the "Auto Collect" mode in 96-well plates on an AccuriC6 flow cytometer (BD, Accuri® Cytometers, Inc., San Diego, CA, US), except for MV from smooth muscle cells (SMCs), which were quantified as previously described \[[@B6-nutrients-11-01114],[@B7-nutrients-11-01114]\]. Specifically, for the detection and quantification of cMV from SMC origin, 5 µL of the cMV suspension were incubated for 20 min at RT in the dark with 5 µL of AV-APC and 5 µL of CD142-FITC (tissue factor, TF) in a final volume of 50 µL ABB. cMV were fixed with 250 µL of ABB/paraformaldehyde 2% for 30 min and centrifuged at 20000× *g* for 30 min to pellet cMV. After eliminating the supernatant, cMV were permeabilized with 45 µL of ABB/saponin 0.1% for 20 min at RT in the dark. After permeabilizing, 5 µL of smooth muscle actin (SMA)-α-PE were added to the cMV suspension, incubated for 20 min at RT in the dark, and finally diluted with ABB prior to flow cytometer analyses.

For all cMV characterization and quantification, acquisition was performed at 2 min per sample. The flow rate was set at 14 µL/min. Forward scatter (FSC), side scatter (SSC), and fluorescence data were obtained with the settings on the logarithmic scale. In addition, cMV were identified and quantified based on their binding to AV and their reactivity to cell-specific mAbs ([Figure 1](#nutrients-11-01114-f001){ref-type="fig"}). To identify positive marked events, thresholds of fluorescence were set based on samples incubated with the same final concentration of isotype-matched control antibodies after titration experiments. The AV binding level was corrected for autofluorescence using fluorescence signals obtained with MV labeled with AV in a calcium-free buffer (PBS). To reduce background noise, buffers were prepared on the same day and filtered through 0.2-µm pore size filters under vacuum.

Data were analyzed with BD CSampler software (version 1.0.264.21, Accuri® Cytometers, Inc.). The cMV concentration (number of cMV per µL of plasma) was determined according to Nieuwland's formula \[[@B12-nutrients-11-01114]\].

2.4. Statistical Analysis {#sec2dot4-nutrients-11-01114}
-------------------------

Statistical analyses were performed using the SPSS Statistical Analysis System (version 23.0, IBM Corp. Armonk, NY). Descriptive statistics (mean ± SD or *n* (%)) were used to describe the characteristics of the patients and the outcome variables. The normality of the variables was assessed with the Shapiro--Wilk test. All variables with a skewed distribution were transformed into their natural logarithms for regression analyses. ANOVA with the Bonferroni post hoc test or *t*-test analyses were conducted to examine the differences in MV concentrations related to cardiovascular risk factors and potential confounding factors and related to groups of the SmartDiet score. A linear regression was performed to investigate the specific influence of covariates in the relationship between diet and cMV. According to the results, we performed Spearman's correlations and multivariate linear regressions adjusted for age, sex, use of fish oil supplements, and smoking history to analyze the main associations between the SmartDiet score and cMV. A two-tail *p*-value of \<0.05 was considered statistically significant.

3. Results {#sec3-nutrients-11-01114}
==========

3.1. Patients' Characteristics {#sec3dot1-nutrients-11-01114}
------------------------------

Patients were divided into three categories according to the SmartDiet score, which was based on the usual intake of the different food groups included in the SmartDiet questionnaire. Group I was defined as ≤ 27 points (*n* = 39, 22.4%), group II as 28--35 points (*n* = 106, 60.9%), and group III as ≥ 36 points (*n* = 29, 16.7%) in the questionnaire, where the higher the score, the healthier the diet, according to the Nordic Nutrition Recommendations \[[@B9-nutrients-11-01114]\]. [Table 3](#nutrients-11-01114-t003){ref-type="table"} shows the characteristics of the 174 patients included in the study according to groups of score. Although cMV concentrations from endothelial cells, erythrocytes, lymphocytes, and monocytes increased over time after an AMI (not shown), the distribution of patients according to the weeks after an AMI was homogeneous within tertiles of adherence to the Nordic diet. Therefore, no statistical interaction was observed between adherence to the Nordic diet and weeks after the AMI at inclusion in the study, for the levels of cMV in the patients studied. The mean age was 75 years, and approximately 60% were hypertensive. Almost all patients were under statin and dual antiplatelet therapy (98% and 95.5%, respectively), 24% were diabetics, 10% were current smokers, and 50% of the study population used fish oil supplements prior to inclusion.

[Figure 2](#nutrients-11-01114-f002){ref-type="fig"} depicts the main cell origin of cMV. No significant differences were observed in the percentage of cMV from each cell origin or in clinical and biochemical characteristics of patients according to groups of diet score.

3.2. Food Items and SmartDiet Score {#sec3dot2-nutrients-11-01114}
-----------------------------------

In general terms, the mean score for each item ([Table 4](#nutrients-11-01114-t004){ref-type="table"}) was higher in group III compared to group II and group I, and also was higher in group II compared to group I for nearly each food item, except for the "mayonnaise, remoulade, and kaviar" and "sweet toppings and sweet drinks" food items, in which no differences were observed between the three groups of the SmartDiet score. Hence, patients in group III had a higher score for almost every food item (12 out of 14) of the questionnaire compared to patients allocated to group II or group I.

3.3. Associations between Circulating Microvesicles and SmartDiet Score {#sec3dot3-nutrients-11-01114}
-----------------------------------------------------------------------

The Spearman's analyses showed an inverse correlation between the SmartDiet score and total AV^+^, and CD61^+^/AV^+^ and CD31^+^/AV^+^ cMV, reflecting platelet activation (*R* = −0.162, −0.176, and −0.159, and *p* = 0.045, 0.029, and 0.049, respectively). Thus, the association between SmartDiet score and these cMV was further analyzed by linear regression, adjusting for age, sex, use of fish oil supplements, and smoking history. Multivariable adjustments did not significantly modify the observed results ([Table 5](#nutrients-11-01114-t005){ref-type="table"}).

As depicted in [Figure 3](#nutrients-11-01114-f003){ref-type="fig"}, patients allocated at the highest score range (healthy diet) had significantly lower total (AV^+^) and platelet (CD61^+^/AV^+^ and CD31^+^/AV^+^) cMV (*p* = 0.028, 0.017, and 0.038, respectively, one-way ANOVA with the Bonferroni post hoc test) compared to patients allocated at the first and second tertiles of score.

4. Discussion {#sec4-nutrients-11-01114}
=============

4.1. Previous Knowledge {#sec4dot1-nutrients-11-01114}
-----------------------

A healthy diet should be the cornerstone of CVD prevention. In this setting, a high adherence to the Nordic diet has been related to reduced blood pressure \[[@B13-nutrients-11-01114]\], improved blood lipid profile \[[@B14-nutrients-11-01114]\] and insulin sensitivity \[[@B15-nutrients-11-01114]\], improved endothelial function \[[@B2-nutrients-11-01114]\], and reduced low-grade inflammation \[[@B16-nutrients-11-01114]\]. However, this is the first time that high adherence to the Nordic diet, assessed through the validated SmartDiet questionnaire (which was particularly developed to evaluate a subject's diet regarding risk of CVD in the context of the Nordic diet), has been related to MV shedding.

4.2. Main Findings of the Study {#sec4dot2-nutrients-11-01114}
-------------------------------

The main finding in this cross-sectional study is that patients with higher adherence to the Nordic diet presented around 32% lower levels of total AV^+^ cMV, 41% lower levels of CD61^+^/AV^+^ cMV, and 30% lower levels of CD31^+^/AV^+^ cMV, compared to patients allocated to the first and second tertiles of score, despite being under dual antiplatelet therapy. No differences in cholesterol levels were observed across tertiles of score, probably because almost all patients were under statin treatment, as per guidelines after an AMI. Taking this into consideration, this inhibitory effect on platelet activation may contribute to the beneficial effects of the Nordic diet, which is associated with reduced mortality in patients with established CVD \[[@B17-nutrients-11-01114]\].

Interestingly, the mean score for each item was higher in group III compared to group II and group I, except for two food items, in which no differences were observed between groups of the SmartDiet score. This observation indicates that the group classification from the SmartDiet questionnaire, at least within the patients included in the study, reflected a dietary pattern rather than high/low consumption of a specific/single food group. Although the SmartDiet questionnaire has been validated by dietary fat and fiber \[[@B9-nutrients-11-01114]\], the protective effects of the Nordic diet may be considered to be a product of the sum of healthy consumption of single food items and should not be only attributed to a single food or food compound.

4.3. Review of Previous Data {#sec4dot3-nutrients-11-01114}
----------------------------

cMV were identified and quantified through AV binding, which has a high affinity for PS and therefore identifies PS externalization. AV^+^ cMV expose PS on their surfaces, providing a catalytic surface for factor X and prothrombin activation, thus promoting thrombin generation and clot formation \[[@B18-nutrients-11-01114]\]. Besides the externalization of PS, which confers procoagulant activity to cMV, cMV were also identified and quantified on the basis of antigens from their cell of origin and on markers of cell activation. In this line, platelet-derived cMV, which contain epitopes and biomolecules from platelets such as CD61 and/or CD31 and account for 74% of cMV AV^+^, amplify platelet activity on coagulation cascade and leukocyte (and platelet) adhesion/activation \[[@B19-nutrients-11-01114]\], promoting inflammation and increasing platelet deposition on damaged arteries and thrombus formation \[[@B18-nutrients-11-01114]\], thus increasing the atherothrombotic burden \[[@B7-nutrients-11-01114]\]. In fact, total AV^+^ and CD31^+^/AV^+^ cMV map and predict coronary atherosclerosis and calcification in familial hypercholesterolemia patients \[[@B20-nutrients-11-01114]\], contributing to an increased risk of a major adverse CV event. Therefore, nutritional strategies to decrease total AV^+^ and platelet-derived cMV release may improve CVD prognosis.

Few studies have analyzed the effects of diet on MV release. Cocoa flavonols have been shown to decrease CD31^+^ cMV concentrations in patients with coronary artery disease after one month of intake \[[@B21-nutrients-11-01114]\], as did one month of an intervention with the Mediterranean diet in elderly healthy individuals \[[@B22-nutrients-11-01114]\]. Supplementation with omega 3 fatty acids has been shown to reduce CD31^+^ \[[@B23-nutrients-11-01114]\] and CD61^+^ \[[@B24-nutrients-11-01114]\] cMV concentrations, and replacement of saturated fats with monounsaturated and omega 6 fatty acids reduced the number of CD31^+^ cMV \[[@B25-nutrients-11-01114]\]. Taking into consideration that the Nordic diet is rich in polyunsaturated fatty acids and polyphenols, our observations are endorsed by the literature.

4.4. Limitations and Scope of Future Studies {#sec4dot4-nutrients-11-01114}
--------------------------------------------

Our study is not exempt from limitations. The current study was performed in elderly patients with a relatively recent AMI, and therefore, these findings may not be extrapolated to healthy subjects or to other AMI populations. In addition, females accounted for only 29% of the study population, and thus sex-specific differences were not analyzed. This was an association study, and therefore it was hypothesis-generating. Although flow cytometry is the most widely used method for MV quantification and characterization, its limit of quantification is ranged between 0.1 and 0.3 µm of particle size. Therefore, MP populations below the limit of quantification were not considered and could be influenced by the Nordic diet quality. Considering all of these aspects, future studies should be focused on the evaluation of the effects of the Nordic diet on MV shedding from different sizes and cell origins through randomized trials, in order to confirm a cause--effect relationship and the potential sex-specific differences in the observed effects.

5. Conclusions {#sec5-nutrients-11-01114}
==============

Dietary habits significantly affect MV shedding, known to directly influence cellular functions. This study showed that the higher the adherence to a healthy Nordic diet was, the lower the levels of total AV^+^ and platelet-derived AV^+^ cMV found in the circulating blood of Norwegian elderly patients with a recent AMI. The lower release of MV may potentially contribute to the beneficial effects of the Nordic diet.
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![Representative plots for MV identification and characterization. (**A**) P1 was set according to cMV size and granularity (defined as \<1 µm). (**B**) Annexin V-APC^+^ cMV (M1) were selected from P1. (**C**) AV^+^ cMV binding PE^+^ (M2)- or (**D**) FITC^+^ (M3)-labeled antibodies were selected from P1 and quantified. Double staining with FITC- and PE-labeled antibodies from M1 (Annexin V^+^ cMV) was also quantified. Here, cMV indicates circulating microvesicles, APC denotes allophycocyanin, FITC indicates fluorescein isothiocyanate, and PE is phycoerythrin.](nutrients-11-01114-g001){#nutrients-11-01114-f001}

![Distribution of cell origins of circulating microvesicles in the 174 patients studied. The pie charts show the distribution of cMV from the patients studied (*n* = 174) by major cell origins, indicated by percentages of each marker relative to cell lineage. Only cMV that were Annexin V-positive were considered. The used markers were CD61 for platelets, CD146 for endothelial cells, CD235ab for erythrocytes, CD45 for total leukocytes, CD3 for lymphocytes, CD14 for monocytes, and SMA-α for smooth muscle cell origins. Other leukocyte-derived cMV were positive for CD45 but negative for CD3 or CD14 staining. The markers used for MV characterization are defined in [Table 2](#nutrients-11-01114-t002){ref-type="table"}. Here, cMV indicates circulating microvesicles.](nutrients-11-01114-g002){#nutrients-11-01114-f002}

![Concentration of circulating microvesicles according to groups of score from the SmartDiet questionnaire. Total cMV concentration (AV^+^), platelet-derived (CD61^+^/AV^+^) cMV, and cMV from activated cells (CD31^+^/AV^+^) concentrations in the three groups of scores. \*Significantly different from the other groups (one-way ANOVA with the Bonferroni posthoc test). The markers used for cMV characterization are defined in [Table 2](#nutrients-11-01114-t002){ref-type="table"}. Group I was defined as ≤27points (*n* = 39, 22.4%), group II as 28--35 points (*n* = 106, 60.9%), and group III as ≥36 points (*n* = 29, 16.7%) in the questionnaire, where the higher the score, the healthier the diet, according to the Nordic Nutrition Recommendations. Here, cMV indicates circulating microvesicles, and AV is Annexin V.](nutrients-11-01114-g003){#nutrients-11-01114-f003}

nutrients-11-01114-t001_Table 1

###### 

Questions and scores of version 3 of the SmartDiet questionnaire used to assess dietary patterns and adherence to the Nordic diet.

                                                                                                                Least Healthy (1 point)                                                More Healthy (2 points)                    Most Healthy (3 points)
  ------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------ ---------------------------------------------------------------------------------------------
  Milk or yogurt                                                                                                                                                                                                                  
  What sort of milk do you use more often?                                                                      whole milk                                                             low-fat milk or no milk at all             skimmed milk
  Cream and sour cream                                                                                                                                                                                                            
  What sort of cream and sour cream do you use more often?                                                      whole cream                                                            light cream                                extra-light cream or less than once weekly consumption
  Cheese                                                                                                                                                                                                                          
  What sort of cheese do you use more often?                                                                    white cheese                                                           light cheese                               cheese with rape and sunflower oil, extra-light cheese or less than once weekly consumption
  Spreading/cured meat                                                                                                                                                                                                            
  What sort of spreading meat do you use more often?                                                            fat meats                                                              \-                                         lean meats or less than once weekly consumption
  Meat for dinner                                                                                                                                                                                                                 
  What sort of meat do you consume for dinner more often?                                                       Fat or processed meat                                                  lean met with fat rim or skin              lean meats or less than once weekly consumption
  Spreading fish                                                                                                                                                                                                                  
  How often do you spread fish in sandwiches or in salads for lunch?                                            up to 1 slice of bread per week or never                               between 2 and 4 slices of bread per week   about 5 or more slices of bread per week
  Fish for dinner                                                                                                                                                                                                                 
  How many times per week do you eat fish, fish products, and/or fish dishes?                                   between once per week and never                                        2 times per week                           3 or more times per week
  Mayonnaise, remoulade, and kaviar                                                                                                                                                                                               
  How often do you use mayonnaise products on bread food?                                                       Up to 1 slice of bread per week or never or 8 or more times per week   2--7 slices of bread per week              \-
  Butter and margarine on bread food                                                                                                                                                                                              
  What sort of butter and margarine do you use more often?                                                      dairy butter                                                           margarine                                  light margarine or low consumption of butter and margarine
  Fat in cooking                                                                                                                                                                                                                  
  What sort of fat do you use more often when frying, baking, or in sauce, such as dressings?                   dairy butter                                                           margarine                                  oils or use of fat for cooking
  Bread and other grain products                                                                                                                                                                                                  
  What sort of bread or grain cereals do you use more often?                                                    white bread or low bread consumption                                   \-                                         whole-grain bread and cereals
  Vegetables, fruits and berries                                                                                                                                                                                                  
  How many portions (150 g, equivalent to approximately 2 carrots or about a big apple) do you consume daily?   fewer than 2 portions (\< 300 g)                                       2--4 portions (300--600 g)                 more than 4 portions (\> 600 g)
  Sweet toppings and sweet drinks                                                                                                                                                                                                 
  How often do you use sweet toppings or drinks with glucose or fructose?                                       3 or more times per day                                                2 times per day                            0--1 times per day
  Chocolate, snacks, cakes and biscuits                                                                                                                                                                                           
  How often do you eat snacks?                                                                                  3 or more times per week                                               2 times per week                           0--1 times per week

The points from each item are summed into a total SmartDiet score classified as \< 27 points, unhealthy; 28--35 points, somewhat healthy; and \>36 points, healthy diet.

nutrients-11-01114-t002_Table 2

###### 

Cell molecules for circulating microvesicle (cMV) identification and characterization.

  mAb                            Alternative Name                  Expression                     Conjugation   Clone           Company
  ------------------------------ --------------------------------- ------------------------------ ------------- --------------- ---------------------
  AV                             PS-binding protein                Widely expressed               APC                           BD Biosciences
  CD142                          Tissue Factor                     Widely expressed               FITC          VD8             Sekisui diagnostics
  *Platelet-Related*                                                                                                            
  CD61                           β~3~-integrin                     Platelets                      PE            VI-PL2          BD Pharmingen
  CD31                           PECAM-1                           Activated Cells                FITC          AC128           Miltenyi Biotec
  CD62P                          P-Selectin                        Platelets                      PE            HI62P           Immunotools
  CD42b                          Glycoprotein Ib alpha chain       Platelets and megakaryocytes   PE            REA185          MACS Miltenyi
  *Endothelial Cell-Related*                                                                                                    
  CD146                          Melanoma Cell Adhesion Molecule   Endothelial Cells              FITC          P1H12           BD Pharmingen
  CD62E                          E-Selectin                        Endothelial Cells              PE            68-5H11         BD Biosciences
  CD309                          VEGFR-2                           HSCs, EPCs, and ECs            FITC          ES8-20E6        MACS Miltenyi
  *Erythrocyte-Related*                                                                                                         
  CD235ab                        Glycophorin A and B               Erythrocytes                   FITC          HIR2            Immunotools
  *Leukocyte-Related*                                                                                                           
  CD45                           Leukocyte Common Antigen          Leukocytes                     PE            MEM-28          Immunotools
  CD3                            T-cell co-receptor                T-Lymphocytes                  FITC          HIT3b           Immunotools
  CD14                           LPS-receptor                      Macrophages, monocytes         PE            M5E2            BD Pharmingen
  CD62L                          L-Selectin                        Leukocytes                     FITC          LT-TD180        Immunotools
  CD11b                          Macrophage-1 Antigen (Mac-1)      Neutrophils, leukocytes        FITC          M1/70.15.11.5   MACS Miltenyi
  *Smooth Muscle Cell-Related*                                                                                                  
  SMA-α                          Smooth Muscle Actin α             Smooth muscle cells            PE            1A4             R&D Systems

APC denotes allophycocyanin; AV, Annexin V; CD, cluster of differentiation; ECs, endothelial cells; EPCs, endothelial progenitor cells; FITC, fluorescein isothiocyanate; HSCs, hematopoietic stem cells; LPS, lipopolysaccharide; mAb indicates monoclonal antibody; PE, phycoerythrin; PECAM-1, platelet endothelial cell adhesion molecule; PS, phosphatidylserine; and VEGFR-2, vascular endothelial growth factor receptor-2.

nutrients-11-01114-t003_Table 3

###### 

Characteristics of the total study population (*n* = 174) and according to the grouping by diet score.

  ----------------------------------------------------------------------------------------------------------------------------------
  Mean ± SD or *n* (%)               All Patients (*n* = 174)   Group I\       Group II (*n =* 106)   Group III (*n* = 29)   *p*
                                                                (*n* = 39)                                                   
  ---------------------------------- -------------------------- -------------- ---------------------- ---------------------- -------
  Weeks after an AMI at inclusion                                                                                            0.994

  2 up to 4 weeks                    90 (52)                    21 (54)        53 (50)                16 (55)                

  4 up to 6 weeks                    41 (24)                    9 (23)         25 (24)                7 (24)                 

  6--8 weeks                         43 (25)                    9 (23)         28 (26)                6 (21)                 

  Males                              124 (71.2)                 28 (71.8)      78 (73.6)              18 (62.1)              0.371

  Age (years)                        75 ± 4                     75 ± 4         74 ± 4                 73 ± 3                 0.403

  BMI (kg/m^2^)                      26.11 ± 4.04               25.77 ± 3.68   26.33 ± 4.46           26.16 ± 3.54           0.803

  Systolic blood pressure (mm Hg)    139 ± 9                    138 ± 23       139 ± 18               130 ± 14               0.092

  Diastolic blood pressure (mm Hg)   75 ± 10                    74 ± 11        76 ± 8                 74 ± 10                0.651

  Total cholesterol (mmol/L)         3.88 ± 0.82                3.74 ± 0.90    3.87 ± 0.83            3.93 ± 0.74            0.410

  HDL cholesterol (mmol/L)           1.38 ± 0.44                1.40 ± 0.52    1.37 ± 0.38            1.42 ± 0.45            0.973

  Total cholesterol/HDL ratio        2.97 ± 0.85                2.79 ± 0.57    2.95 ± 0.82            2.95 ± 0.90            0.867

  LDL cholesterol (mmol/L)           2.16 ± 0.64                2.05 ± 0.59    2.17 ± 0.64            2.2 ± 0.64             0.525

  Triglycerides (mmol/L)             1.30 ± 0.84                1.20 ± 0.33    1.24 ± 0.57            1.40 ± 1.69            0.580

  Glucose (mmol/L)                   6.23 ± 1.97                5.93 ± 1.66    6.22 ± 1.89            5.76 ± 0.98            0.372

  HbA1C (%)                          6.14 ± 1.01                6.08 ± 0.78    6.19 ± 1.12            5.83 ± 0.71            0.246

  Previous hypertension              103 (59.2)                 26 (66.7)      56 (52.8)              21 (72.4)              0.400

  Previous dyslipidemia              78 (44.8)                  15 (38.5)      51 (48.1)              12 (41.4)              0.346

  Previous diabetes                  41 (23.6)                  10 (25.6)      25 (23.6)              6 (20.7)               0.864

  Current smokers                    17 (9.8)                   7 (17.9)       7 (6.6)                3 (10.3)               0.151

  Medication after AMI                                                                                                       

  Acetylsalicylic acid               166 (95.4)                 35 (89.7)      102 (96.2)             29 (100)               0.228

  ADP receptor inhibitors            163 (94.7)                 36 (92.3)      100 (94.3)             27 (93.1)              0.885

  Statins                            170 (97.7)                 38 (97.4)      103 (97.2)             29 (100)               0.692

  Beta blockers                      153 (87.9)                 34 (87.1)      91 (85.8)              28 (96.5)              0.174

  Calcium channel blockers           31 (17.8)                  7 (17.9)       22 (20.7)              2 (6.9)                0.280

  ACE inhibitors                     58 (33.3)                  13 (33.3)      36 (34.0)              9 (31.0)               0.931

  ARB                                44 (25.3)                  8 (20.5)       30 (28.3)              6 (20.7)               0.522

  Nitrates                           21 (12.1)                  3 (7.7)        16 (15.1)              2 (6.9)                0.283

  Diuretics                          41 (23.6)                  8 (20.5)       29 (27.3)              4 (13.8)               0.132

  Anticoagulants                     23 (13.2)                  7 (17.9)       12 (11.3)              4 (13.8)               0.503

  Omega 3 supplements                88 (50.6)                  20 (51.3)      52 (49.1)              16 (55.2)              0.456
  ----------------------------------------------------------------------------------------------------------------------------------

*p* values refer to comparisons between groups of score from the ANOVA test for quantitative variables or the chi-squared test for categorical variables. Group I was defined as ≤ 27points, group II as 28--35 points, and group III as ≥ 36 points in the questionnaire, where the higher the score, the healthier the diet. ADP indicates adenosine diphosphate; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blockers; AMI, acute myocardial infarction; BMI, body mass index; HbA1C, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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###### 

Mean of score for each food item according to groups of the SmartDiet score.

                                           *N* (%)                                           
  ---------------------------------------- --------------- ----------------- --------------- ----------
  Milk or yogurt                           2.0 ± 0.5 ^a^   2.2 ± 0.5 ^a,b^   2.7 ± 0.5 ^b^   0.001
  Cream and sour cream                     1.7 ± 0.8 ^a^   2.5 ± 0.6 ^b^     2.8 ± 0.4 ^b^   \<0.0001
  Cheese                                   1.1 ± 0.3 ^a^   1.6 ± 0.8 ^b^     2.7 ± 0.6 ^c^   \<0.0001
  Spreading/cured meat                     1.7 ± 1.0 ^c^   2.6 ± 0.8 ^b^     3.0 ± 0.0 ^b^   \<0.0001
  Meat for dinner                          1.7 ± 0.9 ^a^   2.6 ± 0.7 ^b^     3.0 ± 0.0 ^b^   \<0.0001
  Spreading fish                           1.8 ± 0.7 ^a^   2.0 ± 0.7 ^a^     2.5 ± 0.7 ^b^   0.027
  Fish for dinner                          1.8 ± 0.7 ^a^   2.2 ± 0.7 ^b^     2.7 ± 0.4 ^c^   \<0.0001
  Mayonnaise, remoulade, and kaviar        1.4 ± 0.5       1.4 ± 0.5         1.4 ± 0.5       0.950
  Butter and margarine on bread food       1.7 ± 1.0 ^a^   2.5 ± 0.8 ^b^     2.9 ± 0.3 ^b^   \<0.0001
  Fat in cooking                           1.4 ± 0.8 ^a^   2.3 ± 0.9 ^b^     2.8 ± 0.4 ^c^   \<0.0001
  Bread and other grain products           1.5 ± 0.9 ^a^   2.5 ± 0.9 ^b^     2.7 ± 0.8 ^b^   \<0.0001
  Vegetables, fruits, and berries          1.5 ± 0.5 ^a^   1.8 ± 0.6 ^b^     2.2 ± 0.4 ^c^   0.003
  Sweet toppings and sweet drinks          2.6 ± 0.5       2.7 ± 0.6         2.9 ± 0.3       0.259
  Chocolate, snacks, cakes, and biscuits   2.1 ± 0.8 ^a^   2.5 ± 0.7 ^b^     3.0 ± 0.0 ^c^   0.001

The results are expressed as mean ± SD of the score (ranging from 1 to 3) for each food item within each group of diet quality classification. *p* is from the ANOVA with the Bonferroni post hoc test comparing the mean scores for each food item between groups of total SmartDiet score. Values in rows with different superscript letters are significantly different. Group I was defined as ≤ 27 points (*n* = 39, 22.4%), group II as 28--35 points (*n* = 106, 60.9%), and group III as ≥ 36 points (*n* = 29, 16.7%) as a product of the sum of the 14 items of the questionnaire, where the higher the score, the healthier the diet, according to the Nordic Nutrition Recommendations.
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###### 

Multivariable adjusted associations between the SmartDiet score and cMV.

  SmartDiet Score                                       
  --------------------------- -------- ------- -------- -------
  *Total cMV (AV^+^)*                                   
   Unadjusted                 −0.179   0.027   \-       \-
   Multivariable adjusted\*   0.275    0.031   −0.190   0.024
  *Platelet-Derived cMV*                                
  CD61*^+^*/AV*^+^*                                     
   Unadjusted                 −0.198   0.014   \-       \-
   Multivariable adjusted\*   0.288    0.043   −0.229   0.006
  CD31^+^/AV^+^                                         
   Unadjusted                 −0.168   0.037   \-       \-
   Multivariable adjusted\*   0.328    0.016   −0.179   0.033

^1^*R-* and *p*-values are from the ANOVA in the linear regression model, and *β^2^*- and *p*-values are for the contribution of the SmartDiet score in the multivariable adjusted model. \*Adjusted for age, sex, use of omega 3 supplements, and smoking history. The markers used for microvesicle (MV) characterization are defined in [Table 2](#nutrients-11-01114-t002){ref-type="table"}. cMV indicates circulating microvesicles, and AV is Annexin V.
